Even as biosimilars of anti–vascular endothelial growth factor (anti-VEGF) agents are coming to market and advancing through the pipeline, a new agent that may have substantial benefits for patients with wet age-related macular degeneration (AMD) has been approved by the FDA: brolucizumab, which sponsor Novartis will sell as Beovu.
Even as biosimilars of anti—vascular endothelial growth factor (anti-VEGF) agents are coming to market and advancing through the pipeline, a new agent that may have substantial benefits for patients with wet age-related macular degeneration (AMD) has been approved by the FDA: brolucizumab, which sponsor Novartis will sell as Beovu.
Brolucizumab is a humanized single-chain antibody fragment with enhanced tissue penetration and rapid clearance from systemic circulation. The structure results in a small molecule, 26 kDa, that allows for the inhibition of all isoforms of vascular endothelial growth factor (VEGF), and that makes the product suitable to deliver high concentrations of the drug.
As such, brolucizumab can be dosed once every 3 months, after a 3-month loading phase, without compromising its efficacy. In fact, in the 2 phase 3 clinical trials on which the product’s approval was based, HAWK and HARRIER, the new anti-VEGF agent was noninferior to fellow anti-VEGF therapy aflibercept (Eylea) at 1 year, despite longer treatment intervals for brolucizumab.
Brolucizumab also resulted in greater reductions in central subfield thickness, an indicator of retinal fluid, at week 16 and at 1 year, versus aflibercept. Both of the anti-VEGF agents had similar safety.
“Beovu is the first to offer less frequent dosing in the first year of therapy while maintaining its effectiveness. This gives more time for wet AMD patients to focus on what’s important in their lives,” said Marie-France Tschudin, president of Novartis Pharmaceuticals, in a statement.
Currently, aflibercept, which is targeted by biosimilar developers including Coherus BioSciences and the Momenta—Mylan partnership, is approved for dosing every 8 weeks or every 4 weeks. In 2018, the FDA also approved an updated label for a modified 12-week dosing schedule. Ranibizumab (Lucentis), targeted by biosimilar developers including Samsung Bioepis, is dosed every 1 month.
While less frequent intravitreal administration of anti-VEGF therapy is likely be a boon for patients, it remains to be seen whether such a benefit will help the newly approved product to overcome the appeal of bevacizumab and its biosimliars.
Bevacizumab, which does not have approved indications for eye disorders, has been shown to be noninferior to aflibercept in terms of visual acuity, and has become a widely used treatment option in lower-resource contexts. The off-label use of the agent has been upheld in the EU Court of Justice, and a recent study from Brazil demonstrated that using bevacizumab left over from oncology applications allowed 96.54% more patients to be treated for eye diseases.
Interest in an ophthalmologic indication for bevacizumab appears to be rising as well; during comments given a recent biosimilars congress, Steinar Madsen, MD, director of the Norwegian Medicines Agency, said that when a drug like bevacizumab sees its patents expire, “It should be taken over by authorities so academic research can result in new indications” that biosimilar developers can then use for their products. Bevacizumab, he said, could be granted indications for eye disorders based on the accumulated evidence available in the scientific literature to date. “That is one of the changes we should have in Europe,” he said.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.